| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 10/23/2008 | US20080261943 Pyrrolopyrimidine a2b selective antagonist compounds, their synthesis and use |
| 10/23/2008 | US20080261942 Combinations of bile acid sequestrant(s) and sterol absorption inhibitor(s) and treatments for vascular indications |
| 10/23/2008 | US20080261941 Inhibitors of fatty acid amide hydrolase; N-pyridin-3-yl-4-(3-{[5-(trifluoromethyl)pyridin-2-yl]oxy}benzylidene)piperidine-1-carboxamide; elevate brain anandamide levels; pain, urinary incontinence, cognitive disorders, anxiety, depression, sleeping, eating, movement disorders, glaucoma, psoriasis |
| 10/23/2008 | US20080261940 N-(1-Arylpyrazol-4L) Sulfonamides and their Use as Parasiticides |
| 10/23/2008 | US20080261939 Stannsoporfin compositions and administration |
| 10/23/2008 | US20080261938 13-Cyclohexyl-5-(2-pyrrolidin-1-ylethoxy)-6,7-dihydro-5H-indolo[2.1-a][2]benzazepine-10-carboxylic acid, for example; use for the treatment or prevention of infection by hepatitis C virus |
| 10/23/2008 | US20080261937 Pharmaceutical compositions and method for treating pediatric hypogonadism |
| 10/23/2008 | US20080261936 Treatment of obesity and/or overweight; comprising, for example, a therapeutically effective amount of oleoyl-estrone in canola oil, wherein the composition is suitable for oral administration |
| 10/23/2008 | US20080261935 Treating pancreatic cancer by administering cardenolide uscharin extracted from Calotropis procera plants |
| 10/23/2008 | US20080261934 Containing a specific number of progesterone-containing daily units A and a specific number of progesterone-containing daily units B for uninterrupted, daily, oral administration; units A contain at most 200 mu g folic acid; units B contain more than 200 mu g folic acid |
| 10/23/2008 | US20080261933 Combination of progesterone-receptor antagonist together with a lutein-hormone-releasing hormone agonist and antagonist for use in brca mediated diseases |
| 10/23/2008 | US20080261932 Methods and compositions for the prevention and/or treatment of an exacerbation of asthma |
| 10/23/2008 | US20080261931 Method and Means of Preventing and Treating Sleep Disordered Breathing |
| 10/23/2008 | US20080261930 Enhancement of activity and/or duration of action of selected anti-inflammatory steroids for topical or other local application |
| 10/23/2008 | US20080261929 Combination of progesterone-receptor antagonist together with an aromatase inhibitor for use in brca mediated diseases |
| 10/23/2008 | US20080261928 Determining whether there is an elevation in marinobufagenin in blood-derived or urine-derived specimens and, if such elevation does exist, concluding that preeclampsia exists; administered orally or by injection; high speed, accurate treatment; reducing blood pressure; hypotensive agents |
| 10/23/2008 | US20080261927 Nutrient phytosterol or phytostanol ester with dispersion aid selected from triglyceride, an essential oil extract, night primrose oil, and/or fish oil; beverages, cosmetics |
| 10/23/2008 | US20080261926 Pharmaceutical Calcimimetics |
| 10/23/2008 | US20080261925 Compounds, compositions, kits and methods of use to orally and topically treat acne and other skin conditions by administering a 19-nor containing vitamin d analog with or without a retinoid |
| 10/23/2008 | US20080261924 Administering a bisphosphonate; risedronate, ibandronate, pamidronate, alendronate, cimadronate, tiludronate; osteoporosis |
| 10/23/2008 | US20080261923 Inhibitory activity against Pin1; inhibit peptidyl-prolyl isomerase activity of Pin1; inhibits growth of cancer cells; Ac-Phe-Tyr-phosphoSer- pseudo amide -Pro-Arg-NH2; Fmoc-bis(POM) phosphoSer- pseudo amide -Pro-2-aminoethyl-(3-indole) and their Phospho-(D)-serine stereoisomers |
| 10/23/2008 | US20080261922 Pharmacological Treatments for Sleep Disorders (Apnoe) With Prostanoid Receptor Antagonists |
| 10/23/2008 | US20080261921 Fused ring heterocycle kinase modulators |
| 10/23/2008 | US20080261920 Treat diseases related to biological function of trace amine associated receptors; depression, anxiety, bipolar, attention deficit hyperactivity, psychosis; includes all racemic mixtures, isomers; (S)-4-(2-chloro-phenyl)-4,5-dihydro-oxazol-2-ylamine |
| 10/23/2008 | US20080261919 Camptothecin-analog with a novel, "flipped" lactone-stable, E-ring and methods for making and using same |
| 10/23/2008 | US20080261918 Silicon Compounds and Their Use |
| 10/23/2008 | US20080261917 Prodrug; novel series of compounds which inhibit the MDM2-p53 interaction and have in vitro activity exerting an anti-tumour effect; cancer |
| 10/23/2008 | US20080261916 Nutraceutical; plant extracts and oils; fructose, glucose, starch, inulin, oligofructoses, fructo-oligosaccharides, lactulose, galactomannan, indigestible polydextrose, acemannan, various gums, indigestible dextrin, phytosterol, phytostanol, vitamins, minerals; symptoms of chronic intestinal inflammation |
| 10/23/2008 | US20080261915 Wound-Healing Pharmaceutical Compositions in the Form of a Sterile Powder Based on Amino Acids and Sodium Hyaluronate |
| 10/23/2008 | US20080261914 Stabilization of vitamin b12 |
| 10/23/2008 | US20080261913 Compounds and pharmaceutical compositions for the treatment of liver disorders |
| 10/23/2008 | US20080261912 For treatment of endocrine-regulated tumors, for example, breast, prostate, ovarian and colon cancers |
| 10/23/2008 | US20080261911 Uses of diphenyl/diphenylamine carboxylic acids |
| 10/23/2008 | US20080261910 Diagnostic Methods Based on Polymorphisms of Glucosyltransferase-Like Protein |
| 10/23/2008 | US20080261909 Gene Delivery to Organs |
| 10/23/2008 | US20080261908 Adverse prognostic markers estrogen receptor, progesterone receptor expression, positive lymph node metastasis, high proliferative index, detectable p53 expression; identify breast cancer-specific signature of miRNAs differentially-expressed in breast cancer cells relative to normal control cells |
| 10/23/2008 | US20080261907 siRNA blocks expression of sphingosine kinase, potentiates effect of radiation in cancer cells of breast, prostate, colorectal, lung, bladder, head and neck, intestine, ovarian, skin; reduces amount of radiation needed to decrease cancer cell viability, tumor size in vivo |
| 10/23/2008 | US20080261906 Screen for agents that modulate replication of hepatitis C virus; detect binding modulators of TBC and NS5A, inhibition of TBC activity, inhibition of Rab1 activity, expression of the TBC protein and/or Rab1 protein |
| 10/23/2008 | US20080261905 Hexoses selected from tetrahydropyran; Preferred are hexitol, altritol, substituted altritols; novel modified nucleosides and nucleotides in single or double stranded oligonucleotides for RNA interference, antisense therapy; inhibit or decrease the expression of P-glycoprotein efflux pumps; cancer |
| 10/23/2008 | US20080261904 Synthesized oligomers complementary to and capable of hybridizing to a selected target nucleic acid; internucleoside linking; three regions differentiated by differentially modified ribofuranosyl sugar moieties; antisense and sense oligomeric compound; inhibiting gene expression |
| 10/23/2008 | US20080261903 Isolated polynucleotide encoding a Regulated in chronic obstructive pulmonary disease Kinase polypeptide; host cell; hybridization; screening; prediction, diagnosis; prognosis; chronic obstructive pulmonary disease, asthma, cancer, diseases of defective cell signaling |
| 10/23/2008 | US20080261902 Pharmaceutical composition containing polydatin and its application |
| 10/23/2008 | US20080261900 Fluoroquinolones |
| 10/23/2008 | US20080261899 AGENT FOR CONTROLLING Bcl-2 EXPRESSION COMPRISING GINSENOSIDE F1 AS AN ACTIVE COMPONENT |
| 10/23/2008 | US20080261898 Composition and method for cancer treatment and prevention |
| 10/23/2008 | US20080261897 Epigallocatechin 3-O-Gallate; for masking bitter taste in tea extracts; fat metabolism; instant powder |
| 10/23/2008 | US20080261896 Testosterone generating and metabolizing enhancer |
| 10/23/2008 | US20080261895 Central nervous system disorders |
| 10/23/2008 | US20080261883 Runx3 gene showing anti-tumor activity and use thereof |
| 10/23/2008 | US20080261882 Methods for Inhibiting Heregulin and Treating Cancer |
| 10/23/2008 | US20080261880 Synthetic approach to designed chemical structures |
| 10/23/2008 | US20080261876 Method for Purifying Marine Collagen and the Processing Thereof Into Porous Sponges |
| 10/23/2008 | US20080261874 Point mutations; single or double alternation of tyrosine and aspartate residues; carcinoma; AIDS; gene therapy |
| 10/23/2008 | US20080261873 Growth-Hormone Secretagogues |
| 10/23/2008 | US20080261866 Compositions Comprising Glycosaminoglycan and Nonsteroidal Anti-Inflammatory Drug |
| 10/23/2008 | US20080261865 Oxidized Lipids and Uses Thereof in the Treatment of Inflammatory Diseases and Disorders |
| 10/23/2008 | US20080261864 Insulin signalling pathway modulators, compounds influencing a dysregulated hepatic glucose production, pyruvate dehydrogenase kinase (PDHK) inhibitors, inhibitors of gastric emptying, insulin, inhibitors of GSK-3, retinoid X receptor (RXR) agonists, agonists of uncoupling protein |
| 10/23/2008 | US20080261862 Integrin mediates proliferative signal provided by CD23 to pre-B cells; immobilized rodent cells; drug screening; anticancer agents; antiinflammatory agents |
| 10/23/2008 | US20080261303 Method and medicament for inhibiting the expression of a given gene |
| 10/23/2008 | US20080261272 reporter system reflecting the transport process that transports GPI-anchored proteins to the cell wall was constructed and compounds inhibiting this process were discovered; antifungal agents; inhibiting expression of cell wall glycoproteins and preventing pathogens from showing pathogenicity; DNA |
| 10/23/2008 | US20080261271 Expression of hiv polypeptides and production of virus-like particles |
| 10/23/2008 | US20080261262 Lysis/Resealing Process and Device for Incorporating an Active Ingredient, in Particular Asparaginase or Inositol Hexaphosphate, in Erythrocytes |
| 10/23/2008 | US20080261228 Using prostate cancer antigen (PCA) expression as evaluative tool in diagnosis/prognosis of cancer |
| 10/23/2008 | US20080260878 Topical; adenosine 5'-monophosphates and salts thereof; arbutins, ellagic acid, 4-alkylresorcinols, linolic acid, tranexamic acid, chamomile extracts, ubiquinones; chloasma, freckles |
| 10/23/2008 | US20080260871 Method and composition for infusing herbal extracts and pharmaceuticals through the skin |
| 10/23/2008 | US20080260868 Folate based composition for neurological and cognitive applications |
| 10/23/2008 | US20080260866 Method for decreasing inflammation and stress in a mammal |
| 10/23/2008 | US20080260861 Modulating Lymphatic Function |
| 10/23/2008 | US20080260859 Dietary supplement to treat dry eye condition; fish oil triglycerides, eicosapentaenoic acid, docosahexaenoic acid, gamma-linolenic acid, zinc sulphate, vitamin E, vitamin C, vitamin B6, vitamin B12; solid, liquid, or gel; glycerol monostearate, lecithin, gelatin |
| 10/23/2008 | US20080260851 Comprised of acrylic acid or acrylamide; well dispersed in water due to their size, and can contain, encapsulate, incorporate, extract and release molecules, such as active molecules, agents, or ingredients, including bioactive molecules |
| 10/23/2008 | US20080260850 Delivery System For Bioactive Agents on the Basis of a Polymeric Drug Carrier Comprising an Amphiphilic Block Polymer and a Polylacticacid Derivative |
| 10/23/2008 | US20080260847 polyglycolic acid or polylactic acid or glycolic acid-lactic acid copolymer as biocompatible polymer having dispersed therein an active agent such as exendin-4; antidiabetic agent |
| 10/23/2008 | US20080260846 Has acceptable biodegradable polymer; polyglycolic acid, polylactic acid; Parkinson's Disease; injectable microspheres, injectable gels and implants; enhanced bioavailability |
| 10/23/2008 | US20080260845 Multiple active drug resin conjugate |
| 10/23/2008 | US20080260844 Solid, Oral, Microparticulate Dosage Form Which Has Been Designed To Prevent Misuse |
| 10/23/2008 | US20080260842 Permeation enhancing compositions for anticholinergic agents |
| 10/23/2008 | US20080260837 Comprising active drug component sparingly soluble to insoluble in water, water soluble low viscosity grade cellulose polymer with viscosity range of 3 to 50 mPa*s as a surfactant, suspending agent and water; storage stability, uniformity and well suited for both geriatric and pediatric administration |
| 10/23/2008 | US20080260835 Bioavailability; solid dispersion; dosage forms |
| 10/23/2008 | US20080260834 Localized delivery of 1,25 D3 directly to target area using biodegradable polymeric matrices maximizes the efficacy of drug while minimizing systemic exposure and toxicity; inhibit tumor viability or proliferation |
| 10/23/2008 | US20080260832 Sustained release intraocular implants and methods for preventing retinal dysfunction |
| 10/23/2008 | US20080260830 suitable for regeneration, growth stimulation and differentiation of various cells, tissues and organs; growth/differentiation factors (GDFs); regeneration of connective tissue including tendon and/or ligament, periodontal or dental tissue including dental implants, neural tissue and sensory tissues |
| 10/23/2008 | US20080260829 Bone morphogenic proteins (bmp); cell adhesion modulating agent; peptidomimetics of cyclic peptides comprising classical cadherin cell adhesion recognition (CAR) sequences; modulate cell adhesion and improve drug delivery |
| 10/23/2008 | US20080260828 Stable solid dispersion of a derivative of vinca alkaloid and process for manufacturing it |
| 10/23/2008 | US20080260827 Continuous dosing schedule of one, two, or three consecutive days per month for osteoporosis, other bone disorders; patient compliance |
| 10/23/2008 | US20080260826 Compressed tablet formulation containing active ingredient 4'-azidocytidine-2', 3', 5'-tri-isobutyrate hydrochloride and ethylene glycol-propylene glycol block copolymer; gel inhibition during formulation; enhanced gastrointestinal dissolution and absorption; hepatitis C virus |
| 10/23/2008 | US20080260825 Methods and Compositions for Reduction of Side Effects of Therapeutic Treatments |
| 10/23/2008 | US20080260824 Bioadhesive Rate-Controlled Oral Dosage Formulations |
| 10/23/2008 | US20080260823 Ease of administration for patients who have difficulty swallowing; side effect reduction; drooling prevention; neurological disorders |
| 10/23/2008 | US20080260821 Berry Preparations and Extracts |
| 10/23/2008 | US20080260820 Providing effective gastrointestinal tract drug delivery; therapeutic protein having primary amino acid sequence modification |
| 10/23/2008 | US20080260817 Such as celecoxib with 2-[3,4-dihydro-4-hydroxy-3-(phenylmethyl)-2H-1-benzopyran-7-yl]-4-(trifluoromethyl)benzoic acid; cyclooxygenase 2 (Cox 2), leukotriene B4 (Ltb4); arthritis |
| 10/23/2008 | US20080260815 Multiparticulates |
| 10/23/2008 | US20080260813 Pharmaceutical composition of topiramate |
| 10/23/2008 | US20080260811 patches has pressure-sensitive adhesive matrix containing a polyisobutylene, free of permeation enhancer, for drug deliverying sufentanil through the skin to provide an analgesic effect, pain management; sustained release, side effect reduction; consistent concentration in blood |
| 10/23/2008 | US20080260807 Water-Soluble Films Comprising Nicotine |
| 10/23/2008 | US20080260804 Inhibiting microorganism adhesion and colonization on extended wear contact lenses; functionalizing and multilayer surface coupling such as polydiallyldimethylammonium chloride using polyacrylic acid and polyallylamine hydrochloride |
| 10/23/2008 | US20080260803 Producing eye insertable drug delivery agent; extruding active ingredient with polyvinyl alcohol free biodegradable polymer |
| 10/23/2008 | US20080260797 Methods of treating disease with nitric oxide (no)-releasing polymers and soluble no-releasing nitrosamines |
| 10/23/2008 | US20080260796 Reduction of infection associated with medical device |
| 10/23/2008 | US20080260791 Reducing pain; in situ administering dosage |